BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brunner SM, Rubner C, Kesselring R, Martin M, Griesshammer E, Ruemmele P, Stempfl T, Teufel A, Schlitt HJ, Fichtner-Feigl S. Tumor-infiltrating, interleukin-33-producing effector-memory CD8(+) T cells in resected hepatocellular carcinoma prolong patient survival. Hepatology 2015;61:1957-67. [PMID: 25645298 DOI: 10.1002/hep.27728] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 9.6] [Reference Citation Analysis]
Number Citing Articles
1 Schoenberg MB, Bucher JN, Koch D, Börner N, Hesse S, De Toni EN, Seidensticker M, Angele MK, Klein C, Bazhin AV, Werner J, Guba MO. A novel machine learning algorithm to predict disease free survival after resection of hepatocellular carcinoma. Ann Transl Med 2020;8:434. [PMID: 32395478 DOI: 10.21037/atm.2020.04.16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
2 Ploeger C, Waldburger N, Fraas A, Goeppert B, Pusch S, Breuhahn K, Wang XW, Schirmacher P, Roessler S. Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukin-6 signaling in hepatocellular carcinoma. Hepatology 2016;64:828-42. [PMID: 27311882 DOI: 10.1002/hep.28684] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
3 Han Z, Yang, Trivett A, Oppenheim JJ. Therapeutic vaccine to cure large mouse hepatocellular carcinomas. Oncotarget 2017;8:52061-71. [PMID: 28881713 DOI: 10.18632/oncotarget.19367] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
4 Schoenberg MB, Bucher JN, Vater A, Bazhin AV, Hao J, Guba MO, Angele MK, Werner J, Rentsch M. Resection or Transplant in Early Hepatocellular Carcinoma. Dtsch Arztebl Int 2017;114:519-26. [PMID: 28835324 DOI: 10.3238/arztebl.2017.0519] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
5 Hong J, Kim S, Lin PC. Interleukin-33 and ST2 Signaling in Tumor Microenvironment. J Interferon Cytokine Res 2019;39:61-71. [PMID: 30256696 DOI: 10.1089/jir.2018.0044] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
6 Morita M, Nishida N, Sakai K, Aoki T, Chishina H, Takita M, Ida H, Hagiwara S, Minami Y, Ueshima K, Nishio K, Kobayashi Y, Kakimi K, Kudo M. Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody. Liver Cancer 2021;10:380-93. [PMID: 34414125 DOI: 10.1159/000516899] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
7 Xia X, Tang P, Liu H, Li Y. Identification and Validation of an Immune-related Prognostic Signature for Hepatocellular Carcinoma. J Clin Transl Hepatol 2021;9:798-808. [PMID: 34966643 DOI: 10.14218/JCTH.2021.00017] [Reference Citation Analysis]
8 Kieler M, Unseld M, Wojta J, Kaider A, Bianconi D, Demyanets S, Prager GW. Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy. Med Oncol 2018;36:1. [PMID: 30426271 DOI: 10.1007/s12032-018-1223-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
9 Tang M, Zhou Q, Huang M, Sun K, Wu T, Li X, Liao B, Chen L, Liao J, Peng S, Chen S, Feng ST. Nomogram development and validation to predict hepatocellular carcinoma tumor behavior by preoperative gadoxetic acid-enhanced MRI. Eur Radiol 2021. [PMID: 33877387 DOI: 10.1007/s00330-021-07941-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Fournié JJ, Poupot M. The Pro-tumorigenic IL-33 Involved in Antitumor Immunity: A Yin and Yang Cytokine. Front Immunol 2018;9:2506. [PMID: 30416507 DOI: 10.3389/fimmu.2018.02506] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
11 Huang R, Chen Z, Li W, Fan C, Liu J. Immune system‑associated genes increase malignant progression and can be used to predict clinical outcome in patients with hepatocellular carcinoma. Int J Oncol 2020;56:1199-211. [PMID: 32319580 DOI: 10.3892/ijo.2020.4998] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
12 Xin H, Liang D, Zhang M, Ren D, Chen H, Zhang H, Li S, Ding G, Zhang C, Ding Z, Wu L, Han W, Zhou W, Chen Y, Luo H, Wang Y, Zhang H, Liu S, Li N. The CD68+ macrophages to CD8+ T-cell ratio is associated with clinical outcomes in hepatitis B virus (HBV)-related hepatocellular carcinoma. HPB (Oxford) 2021;23:1061-71. [PMID: 33309570 DOI: 10.1016/j.hpb.2020.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Castven D, Fischer M, Becker D, Heinrich S, Andersen JB, Strand D, Sprinzl MF, Strand S, Czauderna C, Heilmann-Heimbach S, Roessler S, Weinmann A, Wörns MA, Thorgeirsson SS, Galle PR, Matter MS, Lang H, Marquardt JU. Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas. Oncotarget 2017;8:48688-700. [PMID: 28415775 DOI: 10.18632/oncotarget.16231] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
14 Wan H, Lu S, Xu L, Yuan K, Xiao Y, Xie K, Wu H. Immune-Related Biomarkers Improve Performance of Risk Prediction Models for Survival in Patients With Hepatocellular Carcinoma. Front Oncol 2022;12:925362. [DOI: 10.3389/fonc.2022.925362] [Reference Citation Analysis]
15 Schoenberg MB, Hao J, Bucher JN, Miksch RC, Anger HJW, Mayer B, Mayerle J, Neumann J, Guba MO, Werner J, Bazhin AV. Perivascular Tumor-Infiltrating Leukocyte Scoring for Prognosis of Resected Hepatocellular Carcinoma Patients. Cancers (Basel) 2018;10:E389. [PMID: 30340430 DOI: 10.3390/cancers10100389] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
16 Wang W, Wu J, Ji M, Wu C. Exogenous interleukin-33 promotes hepatocellular carcinoma growth by remodelling the tumour microenvironment. J Transl Med 2020;18:477. [PMID: 33308251 DOI: 10.1186/s12967-020-02661-w] [Reference Citation Analysis]
17 Schoenberg MB, Li X, Li X, Han Y, Hao J, Miksch RC, Koch D, Börner N, Beger NT, Bucher JN, Schiergens TS, Guba MO, Werner J, Bazhin AV. The predictive value of tumor infiltrating leukocytes in Hepatocellular Carcinoma: A systematic review and meta-analysis. Eur J Surg Oncol 2021:S0748-7983(21)00473-X. [PMID: 33966947 DOI: 10.1016/j.ejso.2021.04.042] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Liao H, Zhang Z, Chen J, Liao M, Xu L, Wu Z, Yuan K, Song B, Zeng Y. Preoperative Radiomic Approach to Evaluate Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma Patients Using Contrast-Enhanced Computed Tomography. Ann Surg Oncol. 2019;26:4537-4547. [PMID: 31520208 DOI: 10.1245/s10434-019-07815-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 11.7] [Reference Citation Analysis]
19 Heinrich S, Castven D, Galle PR, Marquardt JU. Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2495. [PMID: 32899197 DOI: 10.3390/cancers12092495] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Villarreal DO, Chin D, Smith MA, Luistro LL, Snyder LA. Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity. Oncotarget 2017;8:39117-30. [PMID: 28388572 DOI: 10.18632/oncotarget.16605] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
21 Liang Y, Wang X, Wang H, Yang W, Yi P, Soong L, Cong Y, Cai J, Fan X, Sun J. IL-33 activates mTORC1 and modulates glycolytic metabolism in CD8+ T cells. Immunology 2021. [PMID: 34411293 DOI: 10.1111/imm.13404] [Reference Citation Analysis]
22 Nagaoka S, Yamada D, Eguchi H, Yokota Y, Iwagami Y, Asaoka T, Noda T, Kawamoto K, Gotoh K, Kobayashi S, Miyoshi E, Doki Y, Mori M. The blockade of interleukin-33 released by hepatectomy would be a promising treatment option for cholangiocarcinoma. Cancer Sci 2021;112:347-58. [PMID: 33098728 DOI: 10.1111/cas.14709] [Reference Citation Analysis]
23 Jin Z, Lei L, Lin D, Liu Y, Song Y, Gong H, Zhu Y, Mei Y, Hu B, Wu Y, Zhang G, Liu H. IL-33 Released in the Liver Inhibits Tumor Growth via Promotion of CD4+ and CD8+ T Cell Responses in Hepatocellular Carcinoma. J Immunol 2018;201:3770-9. [PMID: 30446569 DOI: 10.4049/jimmunol.1800627] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
24 Dominguez D, Zhang Y, Zhang B. IL-33 in Tumor Immunity: Nothing to Sneeze At. Crit Rev Immunol 2018;38:453-70. [PMID: 31002600 DOI: 10.1615/CritRevImmunol.2018026335] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
25 Zeng F, Zhang Y, Han X, Zeng M, Gao Y, Weng J. Employing hypoxia characterization to predict tumour immune microenvironment, treatment sensitivity and prognosis in hepatocellular carcinoma. Comput Struct Biotechnol J 2021;19:2775-89. [PMID: 34093992 DOI: 10.1016/j.csbj.2021.03.033] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Huang CY, Wang H, Liao W, Han F, Li YQ, Chen SW, Lao XM. Transforming Growth Factor β is a Poor Prognostic Factor and Inhibits the Favorable Prognostic Value of CD8+ CTL in Human Hepatocellular Carcinoma. J Immunother 2017;40:175-86. [PMID: 28394813 DOI: 10.1097/CJI.0000000000000166] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
27 Gorbacheva AM, Mitkin NA. Interleukin-33: Friend or Enemy in the Fight against Tumors? Mol Biol 2019;53:681-95. [DOI: 10.1134/s0026893319050066] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
28 Jiang SW, Wang P, Xiang XG, Mo RD, Lin LY, Bao SS, Lu J, Xie Q. Serum soluble ST2 is a promising prognostic biomarker in HBV-related acute-on-chronic liver failure. Hepatobiliary Pancreat Dis Int 2017;16:181-8. [PMID: 28381383 DOI: 10.1016/s1499-3872(16)60185-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
29 He Y, Hwang S, Ahmed YA, Feng D, Li N, Ribeiro M, Lafdil F, Kisseleva T, Szabo G, Gao B. Immunopathobiology and therapeutic targets related to cytokines in liver diseases. Cell Mol Immunol 2021;18:18-37. [PMID: 33203939 DOI: 10.1038/s41423-020-00580-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
30 Wen YH, Lin HQ, Li H, Zhao Y, Lui VWY, Chen L, Wu XM, Sun W, Wen WP. Stromal interleukin-33 promotes regulatory T cell-mediated immunosuppression in head and neck squamous cell carcinoma and correlates with poor prognosis. Cancer Immunol Immunother 2019;68:221-32. [PMID: 30357458 DOI: 10.1007/s00262-018-2265-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
31 Andreone S, Gambardella AR, Mancini J, Loffredo S, Marcella S, La Sorsa V, Varricchi G, Schiavoni G, Mattei F. Anti-Tumorigenic Activities of IL-33: A Mechanistic Insight. Front Immunol 2020;11:571593. [PMID: 33329534 DOI: 10.3389/fimmu.2020.571593] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Jiang W, Lian J, Yue Y, Zhang Y. IL-33/ST2 as a potential target for tumor immunotherapy. Eur J Immunol 2021;51:1943-55. [PMID: 34131922 DOI: 10.1002/eji.202149175] [Reference Citation Analysis]
33 Mukai Y, Yamada D, Eguchi H, Iwagami Y, Asaoka T, Noda T, Kawamoto K, Gotoh K, Kobayashi S, Takeda Y, Tanemura M, Mori M, Doki Y. Vitamin D Supplementation is a Promising Therapy for Pancreatic Ductal Adenocarcinoma in Conjunction with Current Chemoradiation Therapy. Ann Surg Oncol 2018;25:1868-79. [PMID: 29675761 DOI: 10.1245/s10434-018-6431-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
34 Golonka RM, Vijay-Kumar M. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome. Adv Cancer Res 2021;149:171-255. [PMID: 33579424 DOI: 10.1016/bs.acr.2020.10.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
35 Sun Z, Chang B, Gao M, Zhang J, Zou Z. IL-33-ST2 Axis in Liver Disease: Progression and Challenge. Mediators Inflamm 2017;2017:5314213. [PMID: 29180837 DOI: 10.1155/2017/5314213] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
36 Qi L, Zhang Q, Miao Y, Kang W, Tian Z, Xu D, Xiao W, Fang F. Interleukin-33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development. Int J Cancer 2020;146:1421-34. [PMID: 31709531 DOI: 10.1002/ijc.32779] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
37 Trailin A, Červenková L, Ambrozkiewicz F, Ali E, Kasi P, Pálek R, Hošek P, Třeška V, Daum O, Tonar Z, Liška V, Hemminki K. T- and B-Cells in the Inner Invasive Margin of Hepatocellular Carcinoma after Resection Associate with Favorable Prognosis. Cancers (Basel) 2022;14:604. [PMID: 35158872 DOI: 10.3390/cancers14030604] [Reference Citation Analysis]
38 Allegra A, Innao V, Tartarisco G, Pioggia G, Casciaro M, Musolino C, Gangemi S. The ST2/Interleukin-33 Axis in Hematologic Malignancies: The IL-33 Paradox. Int J Mol Sci 2019;20:E5226. [PMID: 31652497 DOI: 10.3390/ijms20205226] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
39 Ringelhan M, Pfister D, O'Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19:222-232. [PMID: 29379119 DOI: 10.1038/s41590-018-0044-z] [Cited by in Crossref: 281] [Cited by in F6Publishing: 289] [Article Influence: 70.3] [Reference Citation Analysis]
40 Yao W, He JC, Yang Y, Wang JM, Qian YW, Yang T, Ji L. The Prognostic Value of Tumor-infiltrating Lymphocytes in Hepatocellular Carcinoma: a Systematic Review and Meta-analysis. Sci Rep 2017;7:7525. [PMID: 28790445 DOI: 10.1038/s41598-017-08128-1] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 11.2] [Reference Citation Analysis]
41 Saranchova I, Han J, Huang H, Fenninger F, Choi KB, Munro L, Pfeifer C, Welch I, Wyatt AW, Fazli L, Gleave ME, Jefferies WA. Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33. Sci Rep 2016;6:30555. [PMID: 27619158 DOI: 10.1038/srep30555] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 5.2] [Reference Citation Analysis]
42 Zhang L, Ding J, Li HY, Wang ZH, Wu J. Immunotherapy for advanced hepatocellular carcinoma, where are we? Biochim Biophys Acta Rev Cancer 2020;1874:188441. [PMID: 33007432 DOI: 10.1016/j.bbcan.2020.188441] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
43 Xu X, Tan Y, Qian Y, Xue W, Wang Y, Du J, Jin L, Ding W. Clinicopathologic and prognostic significance of tumor-infiltrating CD8+ T cells in patients with hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2019;98:e13923. [PMID: 30633166 DOI: 10.1097/MD.0000000000013923] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
44 Zhao Q, Wongpoomchai R, Chariyakornkul A, Xiao Z, Pilapong C. Identification of Gene-Set Signature in Early-Stage Hepatocellular Carcinoma and Relevant Immune Characteristics. Front Oncol 2021;11:740484. [PMID: 34745960 DOI: 10.3389/fonc.2021.740484] [Reference Citation Analysis]
45 Brunner SM, Itzel T, Rubner C, Kesselring R, Griesshammer E, Evert M, Teufel A, Schlitt HJ, Fichtner-Feigl S. Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival. Oncotarget. 2017;8:71002-71011. [PMID: 29050338 DOI: 10.18632/oncotarget.20238] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
46 Dong Y, Wu Z, He M, Chen Y, Chen Y, Shen X, Zhao X, Zhang L, Yuan B, Zeng Z. ADAM9 mediates the interleukin-6-induced Epithelial-Mesenchymal transition and metastasis through ROS production in hepatoma cells. Cancer Lett 2018;421:1-14. [PMID: 29432845 DOI: 10.1016/j.canlet.2018.02.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
47 Ji J, Yin Y, Ju H, Xu X, Liu W, Fu Q, Hu J, Zhang X, Sun B. Long non-coding RNA Lnc-Tim3 exacerbates CD8 T cell exhaustion via binding to Tim-3 and inducing nuclear translocation of Bat3 in HCC. Cell Death Dis. 2018;9:478. [PMID: 29706626 DOI: 10.1038/s41419-018-0528-7] [Cited by in Crossref: 56] [Cited by in F6Publishing: 65] [Article Influence: 14.0] [Reference Citation Analysis]
48 Wasmer MH, Krebs P. The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment. Front Immunol 2016;7:682. [PMID: 28119694 DOI: 10.3389/fimmu.2016.00682] [Cited by in Crossref: 30] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
49 Barnes TA, Amir E. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br J Cancer. 2017;117:451-460. [PMID: 28704840 DOI: 10.1038/bjc.2017.220] [Cited by in Crossref: 163] [Cited by in F6Publishing: 147] [Article Influence: 32.6] [Reference Citation Analysis]
50 Hu W, Li X, Li Q, Tan Y, Xu B, Xie Q, Deng X, Lu B, Jiang J, Wu C. Interleukin-33 Expression does not Correlate with Survival of Gastric Cancer Patients. Pathol Oncol Res 2017;23:615-9. [PMID: 28000059 DOI: 10.1007/s12253-016-0167-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
51 Ding W, Xu X, Qian Y, Xue W, Wang Y, Du J, Jin L, Tan Y. Prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore). 2018;97:e13301. [PMID: 30557978 DOI: 10.1097/md.0000000000013301] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
52 Tian MX, Liu WR, Wang H, Zhou YF, Jin L, Jiang XF, Tao CY, Tang Z, Zhou PY, Fang Y, Qu WF, Ding ZB, Peng YF, Dai Z, Qiu SJ, Zhou J, Lau WY, Fan J, Shi YH. Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma. BMC Med 2019;17:106. [PMID: 31164128 DOI: 10.1186/s12916-019-1341-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
53 Gupta RK, Gupta K, Dwivedi PD. Pathophysiology of IL-33 and IL-17 in allergic disorders. Cytokine & Growth Factor Reviews 2017;38:22-36. [DOI: 10.1016/j.cytogfr.2017.09.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
54 Sun C, Xu J, Song J, Liu C, Wang J, Weng C, Sun H, Wei H, Xiao W, Sun R, Tian Z. The predictive value of centre tumour CD8+ T cells in patients with hepatocellular carcinoma: comparison with Immunoscore. Oncotarget 2015;6:35602-15. [DOI: 10.18632/oncotarget.5801] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 5.4] [Reference Citation Analysis]
55 Afferni C, Buccione C, Andreone S, Galdiero MR, Varricchi G, Marone G, Mattei F, Schiavoni G. The Pleiotropic Immunomodulatory Functions of IL-33 and Its Implications in Tumor Immunity. Front Immunol 2018;9:2601. [PMID: 30483263 DOI: 10.3389/fimmu.2018.02601] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
56 Zhang FP, Huang YP, Luo WX, Deng WY, Liu CQ, Xu LB, Liu C. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment. World J Gastroenterol 2020; 26(2): 134-153 [PMID: 31969776 DOI: 10.3748/wjg.v26.i2.134] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]
57 Itoh S, Yugawa K, Yoshizumi T, Oda Y, Mori M. Immune microenvironment in primary and metastatic liver cancers. Hepatol Res 2021;51:3-4. [PMID: 33354891 DOI: 10.1111/hepr.13607] [Reference Citation Analysis]
58 Schoenberg MB, Anger HJW, Hao J, Vater A, Bucher JN, Thomas MN, Lauseker M, Rentsch M, Schiergens TS, Angele MK, Bazhin AV, Werner J, Guba MO. Development of novel biological resection criteria for safe and oncologically satisfying resection of hepatocellular carcinoma. Surg Oncol 2018;27:663-73. [PMID: 30449490 DOI: 10.1016/j.suronc.2018.08.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
59 Schoenberg MB, Li X, Li X, Han Y, Börner N, Koch D, Guba MO, Werner J, Bazhin AV. The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review. Int Immunopharmacol 2021;101:108220. [PMID: 34673334 DOI: 10.1016/j.intimp.2021.108220] [Reference Citation Analysis]
60 Wang JZ, Zhang YH, Guo XH, Zhang HY, Zhang Y. The double-edge role of B cells in mediating antitumor T-cell immunity: Pharmacological strategies for cancer immunotherapy. Int Immunopharmacol 2016;36:73-85. [PMID: 27111515 DOI: 10.1016/j.intimp.2016.04.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
61 Jevtovic A, Pantic J, Jovanovic I, Milovanovic M, Stanojevic I, Vojvodic D, Arsenijevic N, Lukic ML, Radosavljevic GD. Interleukin-33 pretreatment promotes metastatic growth of murine melanoma by reducing the cytotoxic capacity of CD8+ T cells and enhancing regulatory T cells. Cancer Immunol Immunother 2020;69:1461-75. [PMID: 32285171 DOI: 10.1007/s00262-020-02522-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
62 Li X, Lv Q, Feng Y, Gu Y, Xia R, Ma J, He H, Zhu Y. Interleukin-33, a Potential Cytokine Expressed in the Tumor Microenvironment Is Involved in Antitumor Immunotherapy Through Facilitating CD8 + T Cells. Journal of Interferon & Cytokine Research 2018;38:491-9. [DOI: 10.1089/jir.2018.0069] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
63 Yang H, Xuefeng Y, Jianhua X. Systematic review of the roles of interleukins in hepatocellular carcinoma. Clin Chim Acta 2020;506:33-43. [PMID: 32142718 DOI: 10.1016/j.cca.2020.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
64 Malik A, Thanekar U, Amarachintha S, Mourya R, Nalluri S, Bondoc A, Shivakumar P. "Complimenting the Complement": Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma. Front Oncol 2020;10:627701. [PMID: 33718121 DOI: 10.3389/fonc.2020.627701] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
65 Chen S, Feng S, Wei J, Liu F, Li B, Li X, Hou Y, Gu D, Tang M, Xiao H, Jia Y, Peng S, Tian J, Kuang M. Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging.Eur Radiol. 2019;29:4177-4187. [PMID: 30666445 DOI: 10.1007/s00330-018-5986-x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 13.0] [Reference Citation Analysis]
66 Larsen KM, Minaya MK, Vaish V, Peña MMO. The Role of IL-33/ST2 Pathway in Tumorigenesis. Int J Mol Sci 2018;19:E2676. [PMID: 30205617 DOI: 10.3390/ijms19092676] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]